31 May 2023 | 28:55 min.
Article series – 3 of 3 Insights
The EC pharma and patent package – what’s important to know from a patent law perspective?
End of April, the European Commission presented its draft for a comprehensive reform of pharmaceutical legislation as well as draft regulations that provide for a unitary SPC, a centralised application for “classic” SPCs and an EU wide compulsory license.
It is planning the biggest pharmaceutical reform in 20 years. In particular, the SPC system is to be simplified and streamlined, an EU wide compulsory licensing system shall be implemented in order to tackle future crises and emergencies and questions regarding the possibility to rely on Bolar exemptions are to be clarified.
But what can companies in the sector expect and what issues should they be aware of? Get an overview here.
Download our presentation "The EC pharma and patent package"
Download our presentation: The EC pharma and patent package
The European Commission's pharmaceutical reform package
core objectives and planned changes at a glance
Read the entire articleIn this series
The European Commission's pharmaceutical reform package: core objectives and planned changes at a glance
10 May 2023
The EU Commission's new pharmaceutical package: amended legal framework for data protection, marketing protection and market exclusivity
31 May 2023
The EC pharma and patent package – what’s important to know from a patent law perspective?
31 May 2023
Related Insights
Claiming the clock: Mastering patent limitation periods and their impact on contract design| Life Sciences Quarterly #2
IP: Licensing and insolvency
by multiple authors
